Accession Number:

AD1050996

Title:

Selective AAK1 and GAK Inhibitors for Combating Dengue and Other Emerging Viral Infections

Descriptive Note:

Technical Report,15 Sep 2016,14 Sep 2017

Corporate Author:

Geneva Foundation Tacoma United States

Personal Author(s):

Report Date:

2017-10-01

Pagination or Media Count:

17.0

Abstract:

We discovered an Achilles heel of unrelated viruses a requirement for AP2-associated protein kinase 1 AAK1 and cyclin Gassociated kinase GAK, host kinases that regulate clathrin adaptor proteins-mediated pathways. Our data point to AAK1 and GAK as master regulators of viral infection and attractive targets for broad-spectrum antivirals. We discovered that approved anticancer drugs that target these kinases sunitinib and erlotinib, potently inhibit replication of multiple viruses invitro and reduce mortality in mice infected with DENV and EBOV. This approach is now being advanced to the clinic for both of these indications. Nevertheless, while sunitinib and erlotinib are quite potent inhibitors of AAK1 or GAK, respectively, they are not selective and are therefore associated with toxicity resulting from inhibition of other host cellkinases. The goals of this proposal are to optimize novel, chemically distinct, selective lead AAK1 and GAK inhibitors targeting validated virus-host interactions and already demonstrating great promise against DENV, and advance their development to a near-IND stage. This approach would also protect against biothreat agents from eight viral families, including EBOV and CHIKV.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE